 BOSTON and LOUISVILLE, Ky., Jan. 04, 2022 GLOBE NEWSWIRE -- Talaris Therapeutics, Inc. Nasdaq: TALS, a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022. 